Gandhirajan, Rajesh Kumar
Meyer, Dorothee
Sagwal, Sanjeev Kumar
Weltmann, Klaus-Dieter
von Woedtke, Thomas
Bekeschus, Sander http://orcid.org/0000-0002-8773-8862
Funding for this research was provided by:
Bundesministerium für Bildung und Forschung (03Z22DN11, 03Z22DN11, 03Z22DN11, 03Z22DN11, 03Z22DN11, 03Z22Di1, 03Z22DN11)
Article History
Received: 16 October 2020
Revised: 10 February 2021
Accepted: 26 February 2021
First Online: 25 March 2021
Ethics approval and consent to participate and consent for publication
: Human tumour cell lines: Panc-1 (CRL-1469; ATCC, Manassas, Virginia, USA), HeLa (ATCC CRM-CCL-2), MeWo (ATCC HTB-65), MaMel86a (CVCL A221), Miapaca2GR (ATCC CRM-CRL-1420), OVCAR3 (ATCC HTB-161) and SK-MEL-28 (ATCC HTB-72). Non-tumorigenic human mesenchymal stem cell line: (HMSC; PromoCell, Heidelberg, Germany).
: The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.
: The authors declare no competing interests.
: Funding was received by the German Federal Ministry of Education and Research (BMBF, grant numbers 03Z22DN11 and 03Z22Di1), the German Research Foundation (DFG, grant number AOBJ 669606), as well as the European Social Fund and the Ministry of Education, Science and Culture of Mecklenburg-Vorpommern, Germany (grant number ESF/14-BM-A55-0006-18). D.M. was supported by the Gerhard-Domagk-Foundation in Greifswald, Germany. Open Access funding enabled and organized by Projekt DEAL.